Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the stock.

SYRS has been the subject of a number of other research reports. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Up 1.7 %

SYRS stock opened at $0.24 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The stock has a market capitalization of $6.55 million, a P/E ratio of -0.08 and a beta of 1.34. Syros Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $8.17. The business has a 50-day moving average of $1.48 and a 200-day moving average of $3.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the prior year, the firm posted ($1.35) earnings per share. On average, sell-side analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now directly owns 41,070 shares in the company, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jason Haas acquired 45,344 shares of the stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the transaction, the chief financial officer now directly owns 124,552 shares in the company, valued at approximately $209,247.36. This trade represents a 57.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after purchasing an additional 163,234 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares in the last quarter. Certuity LLC bought a new position in shares of Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth $34,000. 91.47% of the stock is currently owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.